MattBloodMD
banner
doctorblood.bsky.social
MattBloodMD
@doctorblood.bsky.social
Hematology/Internal Medicine Clinician, Researcher, Educator. Thrombosis Medicine, Safe AI, Privacy, Politics and Art.
Reposted by MattBloodMD
Extended-dose DOAC vs full-dose DOAC #Renove trial #ASH24 Late breaking abstract. Officially, reduced dose was not non-inferior, but recurrent #VTE rates were low and there is a substantial reduction in major and non-major bleeding. Congratulations to the French colleagues of #Innovte!
December 10, 2024 at 4:27 PM
Reposted by MattBloodMD
We humbly thank the reviewers for their suggestions. We would like to resubmit this improved manuscript for your consideration. #AcademicSky #MedSky
November 29, 2024 at 4:26 PM
No Apparent Association Between mRNA vaccines and venous thromboembolism
www.sciencedirect.com/science/arti...
No apparent association between mRNA COVID-19 vaccination and venous thromboembolism
By January 2022 over ten billion doses of COVID-19 vaccines had been administered worldwide. Concerns about COVID-19 vaccine-associated thrombosis aro…
www.sciencedirect.com
November 29, 2024 at 11:04 PM
We humbly thank the reviewers for their suggestions. We would like to resubmit this improved manuscript for your consideration. #AcademicSky #MedSky
November 29, 2024 at 4:26 PM
Reposted by MattBloodMD
🎉Congratulations Francis and the 🇫🇷 INNOVTE team for the RENOVE study that will be presented at ASH 2024 @ash-hematology.bsky.social as a Late-Breaking Abstract !
💊Reduced- Vs Full dose of DOAC for long terme anticoagulation after VTE ⤵️
ash.confex.com/ash/2024/web...
Paper: Extended Treatment of Venous Thromboembolism with Reduced- Vs Full-Dose Direct Oral Anticoagulants in Patients at High Risk of Recurrence
ash.confex.com
November 27, 2024 at 3:32 PM